HIMS Stock Surged 39% After Hours: Here's Exactly What Happened

HIMS Stock Surged 39% After Hours: Here''s Exactly What Happened

On Friday, March 7, Hims & Hers Health (NYSE: HIMS) closed the regular session at $15.74, down less than 1%, with investors still nursing the stock''s brutal 48% collapse from its January peak of $31.32. Then Bloomberg broke the news after the bell: Novo Nordisk had agreed to sell its branded weight-loss drugs directly through the Hims platform, ending a legal feud that had nearly gutted the company. HIMS shares jumped to $22 in after-hours trading, a gain of roughly 39% in a matter of hours.

For anyone following this saga, the reversal is genuinely stunning. Just weeks earlier, Novo Nordisk filed a patent infringement lawsuit against Hims after the telehealth company launched a $49-per-month compounded version of Novo''s obesity pill. The FDA piled on, threatening regulatory action against what it called "illegal copycat drugs." Hims pulled the product, but the damage was done. The stock lost nearly half its value in under two months.

From Lawsuit to Partnership in One Month

The speed of this turnaround tells you something important about both companies'' incentives. Novo needs distribution as the GLP-1 obesity drug market grows increasingly competitive, with Eli Lilly and its Zepbound franchise gaining meaningful ground. Reaching Hims'' massive consumer health audience is strategically valuable. Suing your best potential distribution partner is not a winning long-term move.

For Hims, the pivot was existential. The new deal gives the company a legitimate, FDA-approved product to sell. As of Monday March 9, the partnership is officially live. Americans can now access Novo''s NovoCare Pharmacy through the Hims platform, with all Wegovy dose strengths bundled with a Hims membership starting at $599 per month. Both companies are framing this as a "long-term collaboration roadmap," not a one-off arrangement, with a formal joint press release confirming the deal.

The Underlying Business Never Broke

Understanding the size of this after-hours move requires context on how strong the fundamentals remained throughout the regulatory chaos. Hims posted $2.35 billion in full-year 2025 revenue, up 59% year-over-year, with adjusted EBITDA surging nearly 80% to $318 million. Gross margins sit near 75%, which is exceptional for a consumer health platform at this scale. Management guided for $2.7 to $2.9 billion in 2026 revenue, above consensus. The fundamentals never broke. What broke was investor confidence in the regulatory path forward, and Friday''s news resolves that single biggest overhang.

The Eucalyptus Deal Signals a Much Bigger Ambition

The Novo partnership isn''t the only major strategic move Hims has made recently. On February 19, the company announced a $1.15 billion acquisition of Eucalyptus, an Australian digital health platform serving over 775,000 customers with an annual revenue run-rate above $450 million and triple-digit year-over-year ARR growth through 2025. The deal includes $240 million in upfront cash, with the remainder structured as deferred and performance-based earnouts through early 2029, giving Hims balance sheet flexibility.

Eucalyptus operates a portfolio of consumer health brands including Juniper (weight loss), Pilot (men''s health), and Kin (reproductive health) across Australia, the UK, Germany, Japan, and Canada. Combined with prior acquisitions of European telehealth platform Zava and Canadian platform Livewell, Hims is methodically building a genuinely global consumer health platform. As reported by Reuters, the acquisition is expected to close in mid-2026 pending regulatory approvals. The geographic diversification away from the U.S. regulatory environment looks even smarter in hindsight given the turbulence of early 2026.

Is HIMS a Buy at These Levels?

The bull case is real: legitimate GLP-1 distribution, 30%+ projected annual revenue growth, expanding international footprint, and 75% gross margins supporting improving profitability. Analyst consensus before this deal put fair value around $26, implying upside even from post-announcement levels near $22.

The risks are real too. This is Novo and Hims'' second attempt at working together after the first partnership collapsed in 2025. The $599/month Wegovy price point is a significant step up from the $49 compounded version Hims was pitching, and execution on the Eucalyptus integration will take years. Investors evaluating a position today are really asking whether Hims can convert its platform reach into sustainable, diversified revenue growth, an answer that will only become clear over the next several quarters.

---

Disclaimer: This article is for informational purposes only and should not be considered financial advice. Stock investing involves significant risk, including potential loss of principal. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.